ArticleTranslational oncology2026
Integrating single-cell and bulk transcriptomics to identify a SUMOylation-related prognostic signature and the oncogenic role of VPS72 in hepatocellular carcinoma.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatocellular carcinoma (HCC) is a highly aggressive malignancy characterized by limited therapeutic options and significant cellular heterogeneity. This study aims to delineate the SUMOylation-mediated transcriptomic landscape and develop a robust prognostic signature to predict survival and immunotherapy response in HCC patients.
methodsMalignant epithelial cells were classified into SUMOylation-related subtypes using nonnegative matrix factorization. A prognostic signature (SUMOylation.Sig) was constructed via machine learning and validated across multiple cohorts. Immune infiltration, immunotherapy response, and drug sensitivity were evaluated. Furthermore, we performed functional validation of a core signature gene, VPS72, through siRNA-mediated knockdown, colony formation and wound healing assays in HCC cells.
resultsWe identified 10 prognostic SUMOylation-related genes (SRGs) and stratified malignant epithelial cells into five SUMOylation subtypes. The SUMOylation-C4 subtype was associated with favorable outcomes and enhanced immune infiltration. A 13-gene prognostic SUMOylation.Sig was developed and validated, effectively stratifying patients into low- and high-risk categories with distinct survival and responsiveness to immunotherapy. Low-risk patients exhibited increased immune cell infiltration and superior responses to immune checkpoint inhibitors. Experimental validation confirmed differential expression of signature genes in HCC cell lines. Notably, in vitro experiments demonstrated that VPS72 knockdown significantly suppressed the proliferation and migration of HepG2 and LM3 cells, confirming its oncogenic potential.
conclusionsOur study establishes a SUMOylation-based cellular taxonomy and a robust 13-gene prognostic tool for HCC. The experimental validation of VPS72 underscores the functional importance of the signature, suggesting its potential involvement in tumor progression and highlighting potential therapeutic targets for personalized clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.